Amy S. Paller, MD, of Feinberg School of Medicine at Northwestern University, noted that safety is of paramount importance when choosing which systemic therapy to use to treat children with atopic dermatitis (AD).
Amy S. Paller, MD, chair of the department of dermatology at Northwestern University's Feinberg School of Medicine, noted that safety is of paramount importance when choosing which systemic therapy to use to treat children with atopic dermatitis (AD).
Specifically, Paller claimed that biologics are currently the safest to use in children, but she explained that, as more is learned about them, Janus kinase (JAK) inhibitors may take over that title in the years to come.
Conversely, Paller noted that the long-term side effects of systemic therapies are not yet known, which, she emphasized, providers must be aware of when using them to treat children with AD.
Transcript
What are the long-term risks of systemic therapy use in children with AD?
One of the factors that we need to be concerned about with systemic medications in children is that we're talking about longer term than what we may be talking about [for] an adult who's taking a medication. If we start at 2 or 3 years of age, 6 years of age, 10 years of age, we've got a few decades more, potentially, than what we might be doing in treating an adult.
So, we do pay attention to safety; that's of paramount importance in any systemic therapy we choose for children. Right now, we think that the biologics are safest, but we also may, in a few years, as we learn more about the JAK inhibitors, feel very comfortable with their use, including in children who have atopic dermatitis for years on end.
However, of course, it may take a long period of time before we know about the long-term side effects, even of the biologics, and we have to be aware of that in using them for our patients who are very young with atopic dermatitis.
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More